StockWatch
·
Biotechnology: Pharmaceutical Preparations
Quarterly ResultJul 29, 2026, 04:28 PM

Inventiva H1 2026 Cash €166.1M, Short-Term Deposits €67.8M

AI Summary

Inventiva announced preliminary financial results for the first half of 2026, reporting cash and cash equivalents of €166.1 million and short-term deposits of €67.8 million as of June 30, 2026. Net cash used in operating activities was (€48.7) million, while R&D expenses increased to (€50.1) million. The company generated €50.9 million from financing activities, including a €103 million equity offering and €75 million debt financing, partially offset by €62 million EIB loan repayment and €50 million warrant repurchase. Inventiva expects to finance operations until the end of Q2 2027 with existing funds, but notes current cash is insufficient for the next 12 months without further financing.

Key Highlights

  • Cash and cash equivalents totaled €166.1 million as of June 30, 2026.
  • Short-term deposits amounted to €67.8 million as of June 30, 2026.
  • Net cash used in operating activities was (€48.7) million for H1 2026.
  • R&D expenses increased to (€50.1) million in H1 2026 from (€44.9) million in H1 2025.
  • Net cash generated from investing activities was €63.9 million in H1 2026.
  • Net cash generated from financing activities was €50.9 million in H1 2026.
  • No revenues were recorded for H1 2026, compared to €4.5 million in H1 2025.
  • Company expects to finance operations until end of Q2 2027 with current funds.